Skip to main content
APA style

Shirley, P., Turner, N., & Baker, M. . Influenza vaccination: One of our most effective ways to prevent heart attacks and strokes. Public Health Expert Briefing. https://www.phcc.org.nz/briefing/influenza-vaccination-one-our-most-effective-ways-prevent-heart-attacks-and-strokes

Vancouver style

Shirley P, Turner N, Baker M. Influenza vaccination: One of our most effective ways to prevent heart attacks and strokes. Public Health Expert Briefing. . https://www.phcc.org.nz/briefing/influenza-vaccination-one-our-most-effective-ways-prevent-heart-attacks-and-strokes

Summary

The seasonal influenza vaccine doesn’t just reduce the risk and severity of ‘the flu’, it also reduces the risk of non-communicable disease outcomes, notably major cardiovascular events. The incidence of heart attacks and stroke is reduced by about one third. That’s on par with many of the daily heart medications routinely prescribed to high-risk patients. 

For over a century we’ve known that bad flu seasons mean more heart attacks and strokes. Since 2003, strong evidence has emerged demonstrating that the flu vaccine offers substantial cardiovascular protection. This protection comes directly from reducing the risk and severity of influenza, plus likely further non-specific immune protection. Given the huge burden of heart disease and stroke in Aotearoa New Zealand (NZ), we urgently need to highlight these additional hidden benefits and lift vaccination rates among those most at risk.

Influenza doesn’t just make you miserable, it also triggers heart attacks and stokes

Having influenza significantly increases the risk of heart attack and stroke. Epidemiologists first noticed in the 1930s that more people died of cardiovascular causes in severe flu seasons.1 Modern studies back this up. Of note, a large Canadian study found that people who tested positive for influenza had a six‑fold increase in heart attack and stroke risk for at least a week.2  Hospital-based studies show that inpatients with confirmed influenza have a 12% chance of experiencing a major cardiovascular event during their hospitalisation.3

Seasonal influenza vaccination does far more than prevent influenza infection. A growing body of research, which includes dozens of studies and 28 systematic reviews, show the flu vaccination cuts heart attacks and strokes by around one third.4-8

How does influenza cause heart attacks?

Influenza affects the heart and blood vessels in two major ways. First, there are the direct effects of the virus: Influenza can inflame or injure heart muscle directly leading to pericarditis and myocarditis.9,10 More concerning is that it can also replicate within blood vessel walls. This process can destabilise plaques, triggering rupture and clot formation, leading to a heart attack or stroke.9,10 

Second, there are the broader indirect effects of influenza illness: Fever, inflammation, and reduced oxygen levels all place stress on the heart. The inflammatory response also makes blood more prone to clotting and destabilises plaques in blood vessels. This cascade of direct and indirect effects from influenza infection greatly increases the likelihood of adverse cardiovascular events like heart attacks and strokes. No other common infection increases cardiovascular risk to this extent.9,10 

The flu vaccine is as effective as commonly prescribed heart medications at preventing heart attacks and strokes

Research consistently shows that annual influenza vaccination reduces major cardiovascular events by about a third, especially in people already at moderate-to-high cardiovascular risk. This protection is comparable to the effect of cholesterol-lowering medications.4-7,11,12 It is impressive and not well communicated. 

Not only does the annual flu vaccination prevent and reduce severe influenza, but it also provides important cardiovascular protection through “off-target” vaccine effects. Vaccines are increasingly recognised to have pleiotropic effects - boosting the immune system in ways that protect against diseases beyond the intended target.13 Table 1 (see Appendix) shows common vaccines and their recognised benefits in preventing non-communicable diseases, some of which are classified as “off-target”. Some vaccines can induce “trained immunity,” priming the body to respond more effectively to a wide range of infections not just the target disease.14 Influenza vaccination appears to fall into this category, offering a powerful layer of “off-target” cardiovascular protection.4-6 

Summarising the different effects, several recent studies from Scandinavia demonstrate that influenza vaccine appears to prevents cardiovascular events in three different ways; first by preventing influenza, second by stabilising vulnerable plaques inside blood vessels by altering the response to inflammation, and finally by preventing other viral illnesses via trained immunity which can increase the risk of heart attacks and strokes albeit less so than influenza.13, 15,16

Why this benefit matters for Aotearoa New Zealand

Heart disease and stroke remain among the leading causes of death in NZ, accounting for around a third of all deaths, approximately 12,000 each year.17-20 Importantly from an equity perspective, Māori and Pacific peoples bear a disproportionate burden, developing cardiovascular disease earlier and dying from it at higher rates than NZ Europeans.19 Māori have a mortality rate from heart attacks twice that of NZ Europeans with 99.6 deaths per 100,000 people every year. Māori and Pacific people are on average 10 years younger when they are hospitalised with a heart attack or die from it compared to NZ Europeans.21

Yet flu vaccination coverage does not match the need. It tells a very different story.  Only around 60% of New Zealanders over 65 receive the flu vaccine annually with vaccination rates significantly lower among Māori, Pacific, and the most deprived communities - Precisely the groups with the highest cardiovascular risk. Last flu season, 52% of Māori and Pacific people who were eligible for a free influenza vaccine received one compared to 63% of NZ Europeans.22 Another way of looking at it is that there are approximately 372,800 New Zealanders over 65 who are missing out on the annual influenza vaccination, many of them Māori and Pacific people.23

Improving flu vaccine uptake in these groups offers an important, currently underused opportunity to reduce health inequities and prevent thousands of major cardiovascular events. One practical measure would be to reinstate funding for free flu vaccine which had been extended in 2022 and 2023 to all Māori and Pacific people between 55 and 64 years of age to support their access to the vaccine.24

A Clear Call to Action

Cardiovascular diseases are among the biggest health challenges facing NZ. The evidence is clear that flu vaccination can offer as much reduction to risk as the standard medications being prescribed commonly in general practice for prevention of heart attacks and strokes. Importantly, influenza vaccination has an additive protective effect and acts as a complementary intervention alongside blood pressure and cholesterol‑lowering medications.  There are major health gains possible for our communities. Increasing influenza vaccination rates is an effective, feasible, and immediate action with the potential for enormous impact.     

This season’s flu vaccine will be available from multiple outlets from the 1st April 2026.  These outlets include medical centres and many pharmacies. The Vaccine is free if you are over 65, or if your are under 65 and have a listed medical condition.

Patient information about the influenza vaccine is available on the Health NZ site. The Immunisation Advisory Centre (IMAC) website also has further information about influenza and vaccination.  

You can book a vaccination appointment directly on the bookmyvaccine site. This visit is also a good opportunity for a Covid-19 booster if you are eligible.

 

What this Briefing adds

  • Flu vaccination is a simple, safe, widely available intervention that dramatically reduces the risk of major cardiovascular events.
  • This vaccination is disappointingly underutilised, particularly in the groups who could benefit the most.

Implications for policy and practice

  • The NZ health system should use every opportunity to boost flu vaccination coverage among high-risk groups, especially Māori, Pacific, and those living in high deprivation. 
  • Funded vaccine should be offered to Māori and Pacific peoples at younger ages, based on their higher rates of cardiovascular disease in those age groups.
  • Health agencies should emphasise these strong cardiovascular benefits in their annual promotion of flu vaccination.
  • Health practitioners should communicate the powerful cardiovascular protection provided by the flu vaccine to their patients.

Author details

Dr Philip Shirley, Public health Registrar, Immunisation Advisory Centre

Dr Samantha Marsh, School of Population Health, University of Auckland | Waipapa Taumata Rau

Prof Nikki Turner, Department of General Practice and Primary Care, University of Auckland, and Principal Medical Advisor, Immunisation Advisory Centre

Prof Michael Baker, Department of Public Health, Ōtākou Whakaihu Waka, Pōneke | University of Otago, Wellington, and Director, Public Health Communication Centre

Appendix Table 1: Vaccines with known benefits for preventing or reducing non-communicable diseases (NCDs)

Vaccine and mechanismBenefits
1. On-target prevention of infection-related NCDs
HPV vaccineSubstantial reduction in cervical cancer and other associated cancers
Hepatitis B vaccineLiver Cancer and Cirrhosis
Rubella vaccineCongenital disabilities (cardiac, sensory, neurological) in congenital rubella syndrome
PolioPermanent paralysis and neuromuscular disability

Varicella-zoster

(chickenpox) vaccine

Neurological complications, chronic pain syndromes (post-herpetic neuralgia)
Influenza vaccine*Reduced risk of pericarditis and myocarditis
2. Prevention of downstream complications of infection
Haemophilus influenzae type b (Hib) vaccineLong-term neurological disability following meningitis
Neisseria meningitidis vaccineNeurological disability; limb loss from meningococcal sepsis
Streptococcus pneumoniae vaccineReduction in cardiovascular complications following severe infection
Pertussis vaccineNeurological disability from hypoxic brain injury in infants
Measles vaccineNeurological degenerative disease (subacute sclerosing panencephalitis)
Mumps vaccineMale infertility (testicular damage)
Diphtheria vaccineChronic cardiac and neurological damage
Tetanus vaccineLong-term neurological disability following severe disease
Covid-19 vaccineChronic conditions such as Long Covid, cardiovascular and pulmonary complications
Influenza vaccine*Reduced risk of strokes and heart attacks by lowering inflammation and stabilising vulnerable plaques 
3. Off-target (non-specific) effects of vaccines
BCG vaccineReduced risk of Dementia, and allergies, possible immunomodulatory effect on some autoimmune conditions.
Measles vaccineReduced mortality from non-measles infections
Herpes zoster (shingles) vaccineReduction in risk of dementia and cardiovascular adverse events

Influenza Vaccine*

 

Reduced risk of strokes and heart attacks caused by other viral illnesses via trained immunity 

* Note – We have included influenza vaccine in three places to illustrate how it provides cardiovascular protection through three different mechanisms. Many other vaccines have multiple mechanisms of operation, which are not shown.

Creative commons

Public Health Expert Briefing (ISSN 2816-1203)

References

  1. Collins SD. Excess Mortality from Causes Other than Influenza and Pneumonia during Influenza Epidemics. Public Health Rep 1896-1970. 1932;47(46):2159–79. https://doi.org/10.1038/s41581-022-00633-5 
  2. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018 Jan 25;378(4):345–53. https://doi.org/10.1056/NEJMoa1702090 
  3. Chow EJ, Rolfes MA, O’Halloran A, Anderson EJ, Bennett NM, Billing L, et al. Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study. Ann Intern Med. 2020 Oct 20;173(8):605–13. https://doi.org/10.7326/M20-1509 
  4. De Wals P, Desjardins M. Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community. Can Commun Dis Rep. 49(10):433–8. https://doi.org/10.14745/ccdr.v49i10a04 
  5. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015 May 5. https://doi.org/10.1002/14651858.cd005050.pub3 
  6. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016 Dec 15;102(24):1953-1956. https://doi.org/10.1136/heartjnl-2016-309983 
  7. Maniar YM, Al-Abdouh A, Michos ED. Influenza Vaccination for Cardiovascular Prevention: Further Insights from the IAMI Trial and an Updated Meta-analysis. Curr Cardiol Rep. 2022;24(10):1327–35. https://doi.org/10.1007/s11886-022-01748-8
  8. Akhtar Z, Moa AM, Tan TC, Fröbert O, Menzies R, MacIntyre CR. Prevention of Cardiovascular Diseases with Standard-Dose Quadrivalent Influenza Vaccine in People Aged ≥50 Years in Australia During the 2017 A/H3N2 Epidemic. Vaccines. 2025 Apr 14;13(4):407. https://doi.org/10.3390/vaccines13040407 
  9. El Khoury A, Abou Farah J, Saade E. Is Influenza Vaccination Our Best ‘Shot’ at Preventing MACE? Review of Current Evidence, Underlying Mechanisms, and Future Directions. Vaccines. 2025 May 14;13(5):522. https://doi.org/10.3390/vaccines13050522 \
  10. Skaarup KG, Modin D, Nielsen L, Jensen JUS, Biering-Sørensen T. Influenza and cardiovascular disease pathophysiology: strings attached. Eur Heart J Suppl J Eur Soc Cardiol. 2023 Feb 14;25(Suppl A):A5–11. https://doi.org/10.1093/eurheartjsupp/suac117 
  11. Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, et al. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e228873. https://doi.org/10.1001/jamanetworkopen.2022.8873
  12. Byrne P, Demasi M, Jones M, Smith SM, O’Brien KK, DuBroff R. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022 May 1;182(5):474–81. https://doi.org/10.1001/jamainternmed.2022.0134 
  13. Hjelholt AJ, Bergh C, Bhatt DL, Fröbert O, Kjolby MF. Pleiotropic Effects of Influenza Vaccination. Vaccines. 2023 Aug 25;11(9):1419. https://doi.org/10.3390/vaccines11091419 
  14. Ochando J, Mulder WJM, Madsen JC, Netea MG, Duivenvoorden R. Trained immunity — basic concepts and contributions to immunopathology. Nat Rev Nephrol. 2023 Jan;19(1):23–37. doi:10.1038/s41581-022-00633-5
  15. Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021 Nov 2;144(18):1476–84. https://doi.org/10.1161/circulationaha.121.057042 
  16. Fröbert O, Pedersen IB, Hjelholt AJ, Erikstrup C, Cajander S. The flu shot and cardiovascular Protection: Rethinking inflammation in ischemic heart disease. Atherosclerosis. 2026 Mar 1;414:120405. https://doi.org/10.1016/j.atherosclerosis.2025.120405 
  17. Institute for Health Metrics and Evaluation. GBD Compare. Available from: http://vizhub.healthdata.org/gbd-compare
  18. Wheeler A, Rahiri JL, Ellison-Lupena R, Hanchard S, Brewer KM, Paynter J, et al. Assessing the gaps in cardiovascular disease risk assessment and management in primary care for Māori and Pacific peoples in Aotearoa New Zealand— a systematic review. Lancet Reg Health – West Pac. 2025 Mar 1;56. https://doi.org/10.1016/j.lanwpc.2025.101511 
  19. Health status report 2023. New Zealand: Health New Zealand Te Whatu Ora; 2024. https://www.tewhatuora.govt.nz/assets/Publications/Health-status-reports/HNZ-TWO-Health-Status-Report_FULL.pdf 
  20. Mazengarb J, Grey C, Lee M, Poppe K, Mehta S, Harwood M, et al. Inequity in one-year mortality after first myocardial infarction in Māori and Pacific patients: how much is associated with differences in modifiable clinical risk factors? (ANZACS-QI 49). NZMJ. 2020 Sep 4;133(1521):40-54.  https://tinyurl.com/nzmj-cvd 
  21. Kia Manawanui Trust | The Heart of Aotearoa New Zealand. Cardiac Impact Report. Available from: https://www.kmtrust.org.nz/cardiac-impact-report 
  22. National Influenza Vaccine Data - Health New Zealand | Te Whatu Ora. Available from: https://www.tewhatuora.govt.nz/for-health-professionals/data-and-statistics/immunisation/national-influenza-vaccine-data 
  23. Population | Stats NZ. Available from: https://www.stats.govt.nz/topics/population 
  24. Pharmac | Te Pātaka Whaioranga | NZ Government. 2024 . Flu vaccine funded for around one million New Zealanders in 2024. Available from: https://www.pharmac.govt.nz/news-and-resources/news/2024-02-28-media-release-flu-vaccine-criteria-2024

About the Briefing

Public health expert commentary and analysis on the challenges facing Aotearoa New Zealand and evidence-based solutions.

Subscribe

Briefing CTA

Public Health Expert Briefing

Get the latest insights from the public health research community delivered straight to your inbox for free. Subscribe to stay up to date with the latest research, analysis and commentary from the Public Health Expert Briefing.